Inorganic nanoparticles for oral drug delivery: opportunities, barriers, and future perspectives

Asad, Shno; Jacobsen, Ann-Christin; Teleki, Alexandra

doi:10.1016/j.coche.2022.100869

Cited by 24 publications

(9 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scaling up production for clinical applications while maintaining quality and cost-effectiveness remains another limitation for using them. [63][64][65] Optimization strategies and modifications can reduce that limitation. However, for these reasons, the regulatory landscape of inorganic gene delivery is still evolving.…”

Section: Inorganic Nanomaterialsmentioning

confidence: 99%

Nanocarrier-based gene delivery for immune cell engineering

Gharatape,

Sadeghi-Abandansari,

Seifalian

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Inorganic Nanomaterialsmentioning

confidence: 99%

Nanocarrier-based gene delivery for immune cell engineering

Gharatape,

Sadeghi-Abandansari,

Seifalian

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Comparatively to organic materials, inorganic NPs have several advantages, including non-toxic, hydrophilic, biocompatible, and highly stable properties. On the other hand, inorganic materials usually have a smaller particle size, better stability, controlled tunability, greater permeability, and a higher antigen loading than organic materials [ 109 ]. It is becoming increasingly important, particularly for treating gastroenterological (GI) illnesses locally.…”

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

Immobilized nanoparticles-mediated enzyme therapy; promising way into clinical development

et al. 2023

View full text Add to dashboard Cite

Enzyme (Enz)-mediated therapy indicated a remarkable effect in the treatment of many human cancers and diseases with an insight into clinical phases. Because of insufficient immobilization (Imb) approach and ineffective carrier, Enz therapeutic exhibits low biological efficacy and bio-physicochemical stability. Although efforts have been made to remove the limitations mentioned in clinical trials, efficient Imb-destabilization and modification of nanoparticles (NPs) remain challenging. NP internalization through insufficient membrane permeability, precise endosomal escape, and endonuclease protection following release are the primary development approaches. In recent years, innovative manipulation of the material for Enz immobilization (EI) fabrication and NP preparation has enabled nanomaterial platforms to improve Enz therapeutic outcomes and provide low-diverse clinical applications. In this review article, we examine recent advances in EI approaches and emerging views and explore the impact of Enz-mediated NPs on clinical therapeutic outcomes with at least diverse effects. Graphical abstract

show abstract

“…[16][17][18] However, oral drug delivery also has disadvantages, including drug stability in the gastrointestinal tract, first-pass metabolism, poor water solubility, and limited absorption through physiological barriers. 19,20 To address these drawbacks, transdermal drug delivery has emerged as a promising alternative. A transdermal drug delivery system (TDDS) utilizes the skin to administer therapeutic agents.…”

Section: Introductionmentioning

confidence: 99%

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Chu,

Liao,

Liu

et al. 2024

IJN

View full text Add to dashboard Cite

Purpose: Cannabidiol (CBD) is a promising therapeutic drug with low addictive potential and a favorable safety profile. However, CBD did face certain challenges, including poor solubility in water and low oral bioavailability. To harness the potential of CBD by combining it with a transdermal drug delivery system (TDDS). This innovative approach sought to develop a transdermal patch dosage form with micellar vesicular nanocarriers to enhance the bioavailability of CBD, leading to improved therapeutic outcomes. Methods: A skin-penetrating micellar vesicular nanocarriers, prepared using nano emulsion method, cannabidiol loaded transdermal nanocarriers-12 (CTD-12) was presented with a small particle size, high encapsulation efficiency, and a drug-loaded ratio for CBD. The skin permeation ability used Strat-M™ membrane with a transdermal diffusion system to evaluate the CTD and patch of CTD-12 (PCTD-12) within 24 hrs. PCTD-12 was used in a preliminary pharmacokinetic study in rats to demonstrate the potential of the developed transdermal nanocarrier drug patch for future applications. Results: In the transdermal application of CTD-12, the relative bioavailability of the formulation was 3.68 ± 0.17-fold greater than in the free CBD application. Moreover, PCTD-12 indicated 2.46 ± 0.18-fold higher relative bioavailability comparing with free CBD patch in the ex vivo evaluation. Most importantly, in the pharmacokinetics of PCTD-12, the relative bioavailability of PCTD-12 was 9.47 ± 0.88-fold higher than in the oral application. Conclusion: CTD-12, a transdermal nanocarrier, represents a promising approach for CBD delivery, suggesting its potential as an effective transdermal dosage form.

show abstract

Inorganic nanoparticles for oral drug delivery: opportunities, barriers, and future perspectives

Cited by 24 publications

References 80 publications

Nanocarrier-based gene delivery for immune cell engineering

Nanocarrier-based gene delivery for immune cell engineering

Immobilized nanoparticles-mediated enzyme therapy; promising way into clinical development

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Contact Info

Product

Resources

About